1月5日上午，A股三大股指高开高走，沪指重返4000点，超4000只个股上涨，近百只个股涨停。截至午间收盘，沪指报4011.45点，涨1.07%，深证成指涨 1.87%，创业板指涨2.15%。 沪深两市半日成交额达1.64万亿元，较上个交易日放量3238亿元。个股涨多跌少，全市场共4064只个股上涨，99只个股涨停，有1236只个股下跌。 从板块看，保险、医疗器械、半导体、游戏等板块涨幅居前，脑机接口概念股大涨；石油天然气、旅游酒店等板块跌幅居前，海南自贸港概念股持续下 挫。 | | | Wind热门概念指数 | | | | | Wind中国行业指数 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 脑机接口 | 医疗器械 | 保险 | CRO | 存储器 | 保险 | 医疗保健 | 生物科技 | 半导体 | 电脑硬件 | | 9.37% | 6.26% | 5.84% | 5.40% | 5.34% | 5.69% | 4.80% | 3.97% | 3.61% | 3.48% | | 医疗服务 | 创新药 | 基因检 ...

◎记者 时娜 上市公司的回购增持热潮持续至2026年。2026年1月4日，东诚药业、世纪华通等上市公司发布回购股份 计划，宁德时代、美的集团、潍柴动力、蓝思科技等多家深市龙头公司也披露了回购进展情况，英派斯 等公司披露增持计划实施情况，以"真金白银"传递信心，夯实公司价值投资基础。此外，多家上市公司 近日宣布向投资者派发"大红包"。 股份回购是上市公司优化股权结构、提升股东回报的重要抓手。2026年伊始，便有深市上市公司发布股 份回购计划。 东诚药业1月4日公告，计划以集中竞价交易方式回购股份，金额不低于1亿元（含），不超过2亿元 （含），用于实施股权激励和/或员工持股计划。回购价格不超过18.00元/股。 2025年以来，深市上市公司积极回应号召、立足自身发展，持续掀起"真金白银"的回购、增持、分红热 潮，多措并举提升投资者回报，为资本市场健康发展注入强劲动力。 上市公司下"红包雨" 据上海证券报记者不完全统计，2025年12月31日至2026年1月4日晚，仅深市就有15家公司披露半年度或 三季度分红实施公告，相关分红将于2026年1月陆续到账。 其中，天赐材料公告，公司2025年前三季度利润分配预案已获2 ...

Investment Rating - The industry investment rating is "Outperform the Market," indicating an expected performance that exceeds the market by more than 5% over the next six months [29]. Core Insights - The report highlights that the national government will continue to support the renewal of medical equipment in 2026, which is expected to drive demand in the medical device sector. The focus is on high-end equipment and companies with significant performance improvements and international expansion, such as Mindray Medical, United Imaging, Aohua Endoscopy, and Kaili Medical [3]. - The report emphasizes the optimization of application conditions and review processes for equipment renewal projects, aiming to lower investment thresholds and enhance support for small and medium-sized enterprises [3]. - The ongoing policy for equipment renewal is anticipated to sustain a favorable bidding environment for medical devices, with a gradual improvement in performance as inventory clears [3]. Summary by Sections Industry Overview - The report discusses the government's announcement on December 30, 2025, regarding large-scale equipment renewal and the inclusion of various sectors, including healthcare, in the support framework for 2026 [3]. - It outlines the measures to improve the application process for equipment renewal, including stricter requirements for equipment depreciation and minimum usage periods [3]. Investment Opportunities - The report suggests focusing on companies that are expected to show significant performance improvements and have a leading international presence in the medical device sector [3]. - Specific companies recommended for investment include Mindray Medical, United Imaging, Aohua Endoscopy, and Kaili Medical, which are well-positioned to benefit from the anticipated demand for high-end medical equipment [3]. Market Performance - The medical sector has experienced a decline, with a reported drop of 2.06% in the last week, ranking 25th among 28 industries [8][18]. - The report notes that the medical device market is under pressure in the short term due to policy impacts, but improvements are expected as companies innovate and expand internationally [5].

【#深市上市公司回购增持活跃# 2025年披露计划超400单】#去年深市披露回购增持计划超400单# 近年来，在政策推动、企业积极向市场传递发展信心等因素下，深市上市公司回购股份、重要股东增持 等行为持续常态化。 据统计，2025年全年深市共披露回购与增持计划424单，其中回购计划288单，回购金额上限达827.25亿 元；增持计划136单，增持金额上限达315.21亿元。 自回购增持专项贷款落地以来，383家公司及主要股东取得股票回购增持专项贷贷款承诺函，贷款额度 共计829.81亿元。 从行业分布看，电子、生物医药、机械设备、电力设备领域公司成为回购主力军，合计占比达 40.97%，生物医药、机械设备、基础化工、家用电器领域公司成为增持先锋队，合计占比达37.78%， 充分体现了相关实体产业对发展前景的乐观预期。 各行业龙头企业充分发挥"压舱石"作用，以大额回购、持续增持的实际行动引领市场风向。 家用电器龙头企业美的集团基于对公司未来发展前景的信心和公司价值的认可，先后推出二期回购计 划，用于注销减少注册资本、实施股权激励或员工持股计划，截至目前，公司累计回购超100亿元，既 提升股东权益，又绑定核心团队 ...

专家分析指出，回购增持行为既有助于上市公司优化股权结构、提升股东回报，也能有效稳定股价、增 强市场流动性，是市场自我调节机制的重要体现。 龙头引领：标杆效应凸显 护航产业生态 2025年以来，深市上市公司积极回应号召、立足自身发展，持续掀起"真金白银"的回购增持热潮。数据 显示，截至2025年12月31日，深市上市公司共披露回购增持计划424单，回购增持金额上限达1142.46亿 元。 这不仅彰显了公司对自身价值的认可、对长期发展前景的坚定信心，更向市场传递出积极稳健的信号、 增强投资者信心，为资本市场健康发展注入强劲动力。 整体态势：意愿持续高涨 重点行业聚力 2025年，深市上市公司回购增持计划不断涌现，整体呈现"意愿高涨、规模可观、行业集中"的鲜明特 征。 截至2025年12月31日，深市上市公司共披露的424单回购增持计划中，回购计划288单，回购金额上限达 827.25亿元；增持计划136单，增持金额上限达315.21亿元。自回购增持专项贷款落地以来，383家公司 及主要股东取得股票回购增持专项贷贷款承诺函，贷款额度共计829.81亿元。 从行业分布看，电子、生物医药、机械设备、电力设备领域公司成为 ...

上市公司回购增持是"市场之手"与"企业之手"的有效联动。 深市上市公司回购增持计划呈现出重点行业聚力的态势。电子、生物医药、机械设备、电力设备领域公 司成为回购主力军，合计占比达40.97%；生物医药、机械设备、基础化工、家用电器领域公司成为增 持先锋队，合计占比达37.78%，充分体现了相关实体产业对发展前景的乐观预期。 其中，宁德时代公告，截至2025年底，公司以集中竞价交易方式累计回购1599.08万股，占公司同日A股 总股本的0.36%，成交总金额43.86亿元；美的集团累计回购2056.46万股，占总股本的0.27%，支付总金 额为15.1亿元；潍柴动力累计回购5025.25万股，占总股本的0.58%，支付总金额为7.61亿元；蓝思科技 公告累计回购740.96万股，占总股本的0.15%，支付总金额为2.15亿元。 第一财经记者获悉，去年，深市上市公司共披露回购增持计划424单。其中回购计划288单，回购金额上 限达827.25亿元；增持计划136单，增持金额上限达315.21亿元。自回购增持专项贷款落地以来，383家 公司及主要股东取得股票回购增持专项贷贷款承诺函，贷款额度共计829.81亿元。 ...

天眼查工商信息显示，近日，济南迈瑞科技有限公司成立，法定代表人为席彬，注册资本2000万人民 币，经营范围含仪器仪表制造、第一类医疗器械生产、仪器仪表销售、货物进出口、技术进出口、进出 口代理等。股东信息显示，该公司由迈瑞医疗（300760）全资持股。 ...

内容概况：健康服务业市场主体的核心使命在于构建优良的组织环境，通过提供安全、有效、便捷且可 负担的基本医疗与公共卫生服务，全面满足居民各类明确及潜在的健康需求。随着社会进步与生活水平 的整体提升，以及人类生活方式的深刻变革，市场对健康相关产品与服务的总需求正在急剧扩大。以生 物技术和生命科学为引领，覆盖医疗卫生、营养保健、健身休闲等多维功能的健康产业，已成为二十一 世纪推动全球经济发展与社会进步的关键力量。近年来，在行业多项促进政策持续出台、标准体系日臻 完善，以及产业自身发展能力不断增强的共同驱动下，中国健康服务业实现了快速发展，展现出规模持 续扩张、结构不断优化、创新产品与服务层出不穷的蓬勃局面。数据显示，中国健康服务行业市场规模 从2018年的6.37万亿元增长至2024年的9.55万亿元，年复合增长率为6.98%。《"健康中国2030"规划纲 要》提出，2030年中国健康服务业总规模将达16万亿元，行业发展空间巨大。 相关上市企业：美年健康（002044）、通策医疗（600763）、瑞慈医疗（01526）、迈瑞医疗 （300760）、鱼跃医疗（002223）、英科医疗（300677）、晶泰控股（022 ...

Core Viewpoint - The A-share pharmaceutical sector in 2025 exhibits structural differentiation, with innovative drugs and CXO sectors thriving due to overseas demand and business development, while traditional Chinese medicine, medical devices, and pharmaceutical commerce face performance pressures [3][20]. Summary by Category Overall Market Performance - The A-share pharmaceutical and biotechnology sector saw an overall increase of 25.64% from January 1 to December 30, 2025, despite a slight decline in revenue and a stabilization in profits, with total revenue of 18,544.52 billion yuan, down 1.42% year-on-year, and net profit of 1,407.32 billion yuan, down 1.65% year-on-year [4][21]. Innovative Drug Sector - The innovative drug sector was a standout performer in 2025, with the chemical pharmaceutical segment rising by 32.58% and the medical services segment by 32.91% [4][21]. - Companies like BeiGene (百济神州) reported significant growth, achieving revenue of 27.595 billion yuan, a 44.2% increase year-on-year, surpassing the total revenue of 27.21 billion yuan for 2024 [4][22]. Business Development (BD) Trends - The business development landscape for innovative drug companies is evolving, with significant partnerships such as the 11.4 billion USD deal between Innovent Biologics and Takeda, and a 12.5 billion USD collaboration between Hengrui Medicine and GlaxoSmithKline [5][22][24]. - The total value of business development transactions reached approximately 94.158 billion USD in the first three quarters of 2025, significantly exceeding the total for 2024 [25]. CXO Sector Performance - The CXO sector, driven by the demand for innovative drug research, achieved a 32.91% increase in 2025, with total revenue of 1,365.72 billion yuan, up 3.63% year-on-year, and net profit of 209.12 billion yuan, up 36.47% year-on-year [10][27]. - Leading companies like WuXi AppTec (药明康德) and Kanglong Chemical (康龙化成) returned to growth, with WuXi AppTec reporting a revenue increase of 18.61% and net profit growth of 84.84% [28][31]. Traditional Chinese Medicine and Medical Devices - The traditional Chinese medicine sector experienced a modest increase of 6.75% in 2025, with total revenue of 2,590.69 billion yuan, down 4.33% year-on-year, and net profit of 294.99 billion yuan, down 1.53% year-on-year [36]. - The medical device sector reported a revenue of 1,792.10 billion yuan, down 2.24% year-on-year, with notable performance differences among sub-sectors, where companies like Mindray Medical (迈瑞医疗) showed strong overseas revenue growth [33][34].

Group 1 - The core investment theme for the pharmaceutical industry in 2025 is the overseas expansion of innovative drugs, which is expected to yield excess returns compared to the broader pharmaceutical sector and the CSI 300 index [2][21] - The innovative drug index has shown a significant increase, outperforming the pharmaceutical biological index by 37.48 percentage points, with a year-to-date increase of 65.99% [21] - Major transactions in the ADC and dual antibody fields are anticipated to continue, while there is a need to avoid repetitive competition in areas like small nucleic acids and focus on unmet clinical needs [3][4] Group 2 - The report emphasizes the importance of overseas markets for both innovative drugs and medical devices, suggesting that companies should seek growth opportunities beyond domestic market saturation [4][5] - The Chinese pharmaceutical industry is gradually becoming a global innovation center, with significant advancements in dual antibodies and ADCs, while also making strides in emerging fields like small nucleic acids and inhalation formulations [5][6] - The report highlights that the overseas authorization revenue has become a crucial funding source for innovative drug development, with a total upfront payment of $4.551 billion in the first three quarters of 2025 [29][32] Group 3 - The medical device sector is experiencing a shift towards overseas expansion, with a focus on high-value consumables and IVD products, as Chinese companies enhance their market share [7][55] - The export growth of high-value consumables is significant, with a recorded increase of 10.75% in the first half of 2025, particularly in the North American and European markets [57][66] - The report notes that the certification and market establishment processes for high-value consumables are long-term investments, requiring compliance with stringent regulations in the EU and the US [60][61] Group 4 - The recovery of financing in the domestic innovative drug sector has been robust, with a total of 324 financing events amounting to $5.51 billion in the first three quarters of 2025, marking a 67.6% increase year-on-year [70][72] - The CXO industry is experiencing varied recovery rhythms across different segments, with some areas like CDMO seeing order growth due to overseas financing recovery [74]